toggleCaption “>Heidi.news was able to consult the work of a team of Parisian researchers who show an in vitro effect of chlorpromazine against cells infected with Covid-19. Interview with one of the professors who will conduct clinical trials to reposition the oldest antipsychotic in history.
–
Will the fight against the coronavirus go through psychiatry? While professionals expected to be hit hard by the crisis, the Covid-19 psychiatric units remained empty. What suggest a protective effect of certain molecules used in the field. Monday May 6, the Sainte-Anne university hospital group (GHU Paris Psychiatrie et neurosciences) announced the launch of a phase 3 clinical trial (Recovery) to assess the interest of the first antipsychotic in history, chlorpromazine, against Covid-19. Professor Raphaël Gaillard, director of the GHU and co-scientific director of the trial, tells us more about this fascinating track.
This article is for subscribers only.
Log in
–
Access all of our content, support independent writing.
Subscribe
–
–
–
–
–
Every day, the newsletter which will deliver information, testimonies and analyzes to the heart of hospitals.
–
–
